STAT3 and breast carcinoma: Similarly, our pre-clinical evidence that inhibition of the HER2-STAT3-survivin axis increases radiation sensitivity of HER2-positive breast cancers suggests that targeting the HER2-STAT3-survivin axis may be important to overcoming radiotherapy resistance in HER2-positive breast cancers.